AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(Currently amended)** A compound represented by the formula



(I)

wherein Ring A represents ~~an optionally substituted~~a pyridine ring which may have one or two C_{1-4} alkyl groups, X represents ~~an electron-attracting~~a nitrile group, Y represents -CH=CH- or ~~-(CH$_2$)$_2$-~~ -(CH$_2$)$_2$-, R^1 represents (1) a C_{5-7} cycloalkyl group optionally fused with a benzene ring, (2) a C_{7-19} aralkyl group, (3) a 5- or 6-membered heterocyclic ring-C_{1-4} alkyl group or (4) a C_{6-14} aryloxy-C_{1-4} alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C_{1-4} alkyl group, a mono-, di- or tri-halogeno-C_{1-4} alkyl group and a C_{1-4} alkoxy group, and one of R^2 and R^3 ~~each independently represent~~ is a hydrogen atom~~, an optionally substituted hydrocarbon group selected from the group consisting of a C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{6-14} aryl and C_{7-19} aralkyl or an optionally substituted heterocyclic group selected from the group consisting of tetrahydropyranyl, pyranyl and pyridyl~~ or a C_{1-4} alkyl group, and the other is a C_{6-14} aryl group, a C_{7-19} aralkyl group, a C_{3-10} cycloalkyl group, a tetrahydropyranyl group, a pyranyl group or a pyridyl group or a C_{1-6} alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C_{1-4} alkyl group, a mono-, di- or tri- halogeno-C_{1-4}

alkyl group, a C_{1-4} alkoxy group, a C_{1-4} alkoxy-carbonyl group, a cyano group, a C_{1-4} alkyl-carbonylamino group and a hydroxyl group or a salt thereof.

2. (Canceled).

3. (Canceled).

4. (Canceled).

5. (Canceled).

6. (Canceled).

7. (Original) (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.

8. (Canceled).

9. (Currently amended) A ~~medicine~~ vanilloid receptor agonist comprising the compound according to claim 1.

10. (Canceled).

11. (Currently amended) The vanilloid receptor agonist according to claim ~~10~~ 9 which is for local administration.

12. (Currently amended) The vanilloid receptor agonist according to claim ~~10~~ 9 which is an agent for treating overactive bladder.

13. (Currently amended) The vanilloid receptor agonist according to claim ~~10~~ 9 which is an analgesic.

14. (Previously presented) A method of treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1.

15. (Previously presented) An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1.

16. (Canceled).

17. (Canceled).